Physician profile
Jared Kravitz
NPI 1427105212
$8,632.41
in general payments reported to CMS, 2019-2025
47 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,538 · 2021: $585 · 2022: $1,140 · 2023: $1,264 · 2024: $1,328 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,102 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,101.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,254.92 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Covidien LP | $1,170.01 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $891.73 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $555.67 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $543.13 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $470.38 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| United Therapeutics Corporation | $358.86 | 2020-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $343.22 | 2020-2025 | Zerbaxa, Recarbrio, Winrevair |
| Genentech USA, INC. | $331.37 | 2019-2022 | |
| Grifols USA, LLC | $328.42 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $321.21 | 2022-2025 | Acthar |
| Genzyme Corporation | $311.58 | 2022-2025 | |
| Mylan Specialty L.P. | $183.61 | 2019-2024 | Yupelri |
| Abbvie INC. | $179.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $170.23 | 2024-2025 | Dupixent |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $111.36 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $95.44 | 2022-2025 | Tezspire |
| Alexion Pharmaceuticals, INC. | $85.90 | 2021-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $83.27 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $56.10 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $53.05 | 2019 | |
| Aimmune Therapeutics, INC. | $50.60 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $48.87 | 2019-2021 | |
| Allergan, INC. | $48.44 | 2019 | |
| La Jolla Pharmaceutical Company | $39.39 | 2025 | Giapreza |
| Tactile Systems Technology INC | $38.61 | 2025 | Flexitouch Plus, Nimbl |
| Vapotherm INC | $37.68 | 2022 | |
| Shionogi INC | $35.09 | 2022 | |
| Viatris Specialty LLC | $33.54 | 2025 | Yupelri |
| Liquidia Technologies, INC. | $32.79 | 2025 | Yutrepia |
| Circassia INC. | $32.45 | 2019-2020 | |
| Philips North America LLC | $32.14 | 2022-2025 | Vest Therapy Und |
| Pfizer INC. | $31.88 | 2023-2025 | |
| Inogen, INC. | $31.10 | 2022 | |
| Sunovion Pharmaceuticals INC. | $30.70 | 2019-2020 | |
| Sandoz INC. | $28.29 | 2024 | Treprostinil |
| Pharming Healthcare, INC. | $26.80 | 2023 | Ruconest |
| Portola Pharmaceuticals, LLC | $22.97 | 2019 | |
| Electromed, INC. | $19.89 | 2023 | Smartvest |
| Astellas Pharma US INC | $16.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.92 | 2024 | Xarelto |
| Verona Pharma, INC. | $15.85 | 2025 | Ohtuvayre |
| Zoll Circulation INC | $15.79 | 2022 | |
| Phadia US INC. | $15.33 | 2025 | Immunocap |
| Ambu INC. | $14.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.40 | 2019 | |
| Endogastric Solutions, INC | $5.46 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Kravitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.